Currently, there are 382.00M common shares owned by the public and among those 342.64M shares have been available to trade.
The company’s stock has a 5-day price change of -9.16% and -48.45% over the past three months. MRNA shares are trading -20.58% year to date (YTD), with the 12-month market performance down to -29.44% lower. It has a 12-month low price of $62.55 and touched a high of $170.47 over the same period. MRNA has an average intraday trading volume of 3.95 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.47%, -27.96%, and -25.59% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Moderna Inc (NASDAQ: MRNA) shares accounts for 67.95% of the company’s 382.00M shares outstanding.
It has a market capitalization of $30.36B and a beta (3y monthly) value of 1.69. The earnings-per-share (ttm) stands at -$15.38. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.29% over the week and 5.19% over the month.
Earnings per share for the fiscal year are expected to increase by 26.10%, and 20.68% over the next financial year.
Looking at the support for the MRNA, a number of firms have released research notes about the stock. Deutsche Bank stated their Hold rating for the stock in a research note on August 07, 2024, with the firm’s price target at $85-$80. RBC Capital Mkts coverage for the Moderna Inc (MRNA) stock in a research note released on August 05, 2024 offered a Sector Perform rating with a price target of $90. HSBC Securities was of a view on February 26, 2024 that the stock is Reduce, while Oppenheimer gave the stock Outperform rating on January 02, 2024, issuing a price target of $142. Canaccord Genuity on their part issued Hold rating on November 29, 2023.
